Latest debt-to-equity ratio
Neurocrine Biosciences Debt-to-equity ratio
Direct answer
Neurocrine Biosciences's debt-to-equity ratio is 12.5%.
The verified market snapshot reports 12.5%.
Bullstory displays the reported value and does not estimate missing data.
Market data checked October 21, 2026.
Get free Neurocrine Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Debt-to-equity ratio
- 12.5%
Explore related company data
View Neurocrine Biosciences's market capitalizationView Neurocrine Biosciences's p/e ratioView Neurocrine Biosciences's price-to-book ratioView Neurocrine Biosciences's return on equityView Neurocrine Biosciences's dividend yieldView Neurocrine Biosciences's 52-week price rangeView Neurocrine Biosciences's revenue growthView Neurocrine Biosciences's profit marginView all Neurocrine Biosciences key metricsReturn to Neurocrine Biosciences profile